Iben Kümler

3PUBLICATIONS
0CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jun 15, 2019
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.

Iben Kümler, Eva Balslev, Jan Stenvang

|Apr 06, 2019
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.

I Kümler, R L Eefsen, Peter Grundtvig Sørensen

|Nov 09, 2018
Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.

I Kümler, P Grundtvig Sørensen, J Palshof

Pageof 1

Frequent Collaborators